Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Allan Boomer's Momentum Advisors Announces Scholarship for Aspiring Finance and Wealth Management Professionals
-
Dr. Michael Rimlawi Unveils Scholarship for Future Doctors to Support Aspiring Physicians in Shaping Healthcare's Future
-
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
-
Vivienne Westwood dazzles at Barcelona Bridal Night with an epic show
-
Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Ann
-
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
-
Class Action Filed to Recover Wisconsin Tax Foreclosure Takings
-
Hyosung Urges Operators of All ATMs to Follow Previous Security Guidance Due to Large-Scale Cyberattacks
-
Southern California Cities Honor Reproductive Partners Medical Group During National Infertility Awareness Week
-
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
-
Baidu Launches ERNIE 4.5 Turbo, ERNIE X1 Turbo and New Suite of AI Tools to Empower Developers and Supercharge AI Innovation
-
Cash Out On My Home: The Cash Home Buying Company Chattanooga Homeowners Trust to Sell Their House Fast, As-Is, and for a Fair Price
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Northrop Grumman Corporation – NOC
-
Ordoro Enhances B2B Fulfillment with MarketTime Integration
-
Webstar Technology Group to Leverage Blockchain Tokenization for Real Estate Projects
-
Bantam Pharmaceutical Presents New Preclinical Data for BTM-3566 at the American Association for Cancer Research (AACR) Annual Meeting 2025
-
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
-
NASA Invites Local Middle Schoolers to Explore Agency STEM Careers
-
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
-
Harbinger Health Unveils Promising New Data on Early Cancer Detection Platform at AACR 2025
-
DTE Completes Construction on Pine River Solar Park
-
Rgenta Therapeutics Presents Preclinical Data on RGT-61159, a Potent, Selective Oral Small Molecule Inhibitor of MYB, Demonstrating Robust Anti-Tumor Activity in Several Monotherapy Models of AML and
-
CDR-Life Presents Promising Preclinical Data for Novel T Cell Engager Programs at AACR Annual Meeting 2025
-
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer
-
Riunite Joins the 2025 Tequila & Taco Music Festival as Official Wine Sponsor
-
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
-
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
-
Talus Bio Presents Preclinical Data on Transcription Factor Therapeutic Programs at the AACR Annual Meeting 2025
-
FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patie
-
Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Pre
-
Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
-
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
-
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
-
CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025
-
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
-
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
-
Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway
-
Experian Earns NASWA’s Outstanding Performance Award for Second Consecutive Year
-
EU Commission Unhappy as ECB Raises Concerns about Trump’s Impact on Crypto Laws
-
How Pacific Countries are Adopting Clean Energy Practices
-
UN Report Says Illegal Crypto Mining is Fueling Cybercrime Syndicates
-
D-Wave Quantum Inc. (NYSE: QBTS) and Japan Tobacco Complete Quantum AI Project Designed to Improve Drug Discovery Outcomes
-
SAG HOLDINGS LIMITED CHANGE ITS NAME TO INNEOVA HOLDINGS LIMITED
-
Towards the Light: Co-creating a New Global Journey in the AI Field — The Grand 2025 AI Intelligent Development Summit
-
Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025
-
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
-
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
-
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
-
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
